BRAF and neoplasm: However, the onset of tumor resistance observed following this treatment, which was found to be related to the emergence of bypass mutations in resistant tumors that often cause reactivation of the RAS/BRAF/MEK pathway [9,10], led to the development of combo therapies with BRAF and MEK inhibitors as the current standard of care [11,12,13].